alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 88, Number 189 (Monday, October 2, 2023)]
[Notices]
[Page 67771]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-21593]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney Diseases; 
Notice of Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Diseases Special Emphasis Panel; PAR22-069 RC2 Review: 
Biomimetic MPS to Enable Precision Medicine.
    Date: November 17, 2023.
    Time: 11:30 a.m. to 1:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, NIDDK, Democracy II, Suite 
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Ann A. Jerkins, Ph.D., Scientific Review 
Officer, NIDDK/Scientific Review Branch, National Institutes of 
Health, 6707 Democracy Boulevard, Room 7119, Bethesda, MD 20892-
2542, (301) 594-2242, <a href="/cdn-cgi/l/email-protection#d8b2bdaab3b1b6abb998b6b1bcbcb3f6b6b1b0f6bfb7ae"><span class="__cf_email__" data-cfemail="94fef1e6fffdfae7f5d4fafdf0f0ffbafafdfcbaf3fbe2">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: September 26, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-21593 Filed 9-29-23; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
1.
    
    I have reviewed this report on Form 10-K and all reports on Form 10-D required
to be filed in respect of the period covered by this report on Form 10-K of Principal
Life Income Fundings Trust 2008-055 (the Exchange Act periodic reports);2.
    
    Based on my knowledge, the Exchange Act periodic reports, taken as whole, do
not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report;3.
    
    Based on my knowledge, all of the distribution, servicing and other information
required to be provided under Form 10-D for the period covered by this report is
included in the Exchange Act periodic reports;4.
    
    Based on my knowledge and the servicer compliance statement(s) required in this
report under Item 1123 of Regulation AB, and except as disclosed in the Exchange Act
periodic reports, the servicer has fulfilled its obligations under the servicing
agreement(s) in all material respects; and5.
    
    All of the reports on assessment of compliance with servicing criteria for
asset-backed securities and their related attestation reports on assessment of
compliance with servicing criteria for asset-backed securities required to be included
in this report in accordance with Item 1122 of Regulation AB and Exchange Act Rules
13a-18 and 15d-18 have been included as an exhibit to this report, except as otherwise
disclosed in this report. Any material instances of noncompliance described in such
reports have been disclosed in this report on Form 10-K.
   /s/ Dwight N. Soethout

Dwight N. SoethoutVice President  Principal Life Insurance Company
* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not be

published and is not precedent except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

April 2, 2004

Charles R. Fulbruge III

Clerk

 UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 03-40885

Summary Calendar

 

CHARLIE J. LONG,

 PetitionerAppellant,

versus

DOUG DRETKE, DIRECTOR, 

TEXAS DEPARTMENT OF CRIMINAL JUSTICE, 

CORRECTIONAL INSTITUTIONS DIVISION,

 RespondentAppellee.

------------------------------------------------------------

Appeal from the United States District Court

for the Eastern District of Texas

USDC No. 6:02-CV-354

------------------------------------------------------------

Before SMITH, DeMOSS AND STEWART, Circuit Judges.

PER CURIAM:*

Charlie J. Long (“Long”), Texas prisoner # 902617, appeals the district court’s denial of his

petition for a writ of habeas corpus pursuant to 28 U.S.C. § 2254. Long’s petition stems from his

1999 conviction for aggravated assault, for which he isserving a 20-yearsentence. The district court
 

 

-2-

granted Long a certificate of appealability on the sole issue whether Long was deprived of his right

to compulsory process under the Sixth Amendment when a defense witness asserted his Fifth

Amendment right against self-incrimination upon the advice of an attorney appointed to represent the

witness. The state courts rejected this claim on the merits. Long also has filed a motion for leave to

file an out-of-time reply brief of excess length; that motion is GRANTED.

Contrary to Long’s assertion, the record does not support a determination that the witness’s

invocation of his Fifth Amendment right was anything but voluntary. Further, once the witness

appeared in court and refused to testify, Long’s Sixth Amendment compulsory process rights were

exhausted, regardless of the reason for invoking the Fifth Amendment. See United States v. Griffin,

66 F.3d 68, 70 (5th Cir. 1995); United States v. Follin, 979 F.2d 369, 374 (5th Cir. 1992).

Accordingly, the state court’s rejection of Long’s Sixth Amendment claim was not based on an

unreasonable application of clearly established federal law, as determined by the Supreme Court, and

Long is not entitled to federal habeas corpus relief. See 28 U.S.C. § 2254(d)(1).

AFFIRMED.
From: mheath1@twcny.rr.com

To: E-OHPSCA2713.EBSA

Subject: Comment: RIN 1210-AB44

Date: Wednesday, September 07, 2011 9:31:23 PM

You go girl. Keep religious influence out of politics and religous nut jobs on the fringe - where they

belong.

Sincerely,

Michael Heath

Fayetteville, NY 13066
Exhibit 32.1



HYDRODYNEX, INC.



SECTION 1350 CERTIFICATIONS



In connection with the periodic Report of HYDRODYNEX, INC., a Nevada corporation (the Company), on Form 10-K for the period ended June 30, 2008, as filed with the Securities and Exchange Commission (the Report), I, RON KUNISAKI, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:



(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and



(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.



This Certification has not been, and shall not be deemed, filed with the Securities and Exchange Commission.



Date: March 12, 2009

| |              |                 
| | ------------ | ----------------
| |              |                 
| |             
| | By:          | /s/ Ron Kunisaki
| | Ron Kunisaki
| |             



In connection with the periodic Report of HYDRODYNEX, INC., a Nevada corporation (the Company), on Form 10-K for the period ended June 30, 2008, as filed with the Securities and Exchange Commission (the Report), I, RICHARD KUNISAKI, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:



(1) the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and



(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.



This Certification has not been, and shall not be deemed, filed with the Securities and Exchange Commission.



Date: March 12, 2009

| |                  |                     
| | ---------------- | --------------------
| |                  |                     
| |                 
| | By:              | /s/ Richard Kunisaki
| | Richard Kunisaki
<TABLE> <S> <C>

<ARTICLE>                            5
<LEGEND>
THIS  SCHEDULE   CONTAINS   SUMMARY   FINANCIAL   INFORMATION   EXTRACTED   FROM
INTERNATIONAL  TOURIST  ENTERTAINMENT   CORPORATION  MARCH  31,  1999  FINANCIAL
STATEMENTS  AND IS QUALIFIED  IN ITS  ENTIRETY BY  REFERENCE  TO SUCH  FINANCIAL
STATEMENTS.
</LEGEND>
       
<S>                                     <C>
<PERIOD-TYPE>                           3-MOS
<FISCAL-YEAR-END>                       DEC-31-1999
<PERIOD-END>                            MAR-31-1999
<CASH>                                                  146,472
<SECURITIES>                                                  0
<RECEIVABLES>                                            19,183
<ALLOWANCES>                                                  0
<INVENTORY>                                             112,125
<CURRENT-ASSETS>                                        491,636
<PP&E>                                                7,259,286
<DEPRECIATION>                                        1,413,668
<TOTAL-ASSETS>                                        7,440,716
<CURRENT-LIABILITIES>                                   708,193
<BONDS>                                                       0
<PREFERRED-MANDATORY>                                         0
<PREFERRED>                                                   0
<COMMON>                                                  7,938
<OTHER-SE>                                            2,909,101
<TOTAL-LIABILITY-AND-EQUITY>                          7,440,716
<SALES>                                                 578,066
<TOTAL-REVENUES>                                        578,066
<CGS>                                                   540,829
<TOTAL-COSTS>                                         1,041,338
<OTHER-EXPENSES>                                              0
<LOSS-PROVISION>                                              0
<INTEREST-EXPENSE>                                       82,101
<INCOME-PRETAX>                                        (541,978)
<INCOME-TAX>                                                  0
<INCOME-CONTINUING>                                    (541,978)
<DISCONTINUED>                                                0
<EXTRAORDINARY>                                               0
<CHANGES>                                                     0
<NET-INCOME>                                           (541,978)
<EPS-PRIMARY>                                             (0.07)
<EPS-DILUTED>                                             (0.07)
        

</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Antitrust Division

                    Notice is hereby given that, on July 14, 2023, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301*et seq.*                     (“the Act”), the Defense Electronics Consortium (“DEC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, 3D Glass Solutions, Inc., Albuquerque, NM; Amida Technology Solutions LLC, Washington, DC; Ceritas, Inc., Gloucester, MA; CoolCAD Electronics LLC, College Park, MD; Spectrum Control, Inc., Fairview, PA; Synopsys, Inc., Mountainview, CA; and University of Florida Board of Trustees, Gainesville, FL, have been added as parties to this venture.                

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and DEC intends to file additional written notifications disclosing all changes in membership.

                    On April 12, 2023, DEC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the                     **Federal Register**                     pursuant to section 6(b) of the Act on August 8, 2023 (88 FR 53520).                

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2023-20951 Filed 9-26-23; 8:45 am]

BILLING CODE P
No. 60226.

protests 281641-K, etc. (New York).

#### Accessocraft Products Co. et al. *v.*United States,

*357Opinion by

Wilson, J.

In accordance with stipulation of counsel that the merchandise is the same in all material respects as that the subject of Abstract 59105, the merchandise was held dutiable as follows: (1) The items marked with the letter “A” at 10 percent under the provision in paragraph 1528, as modified by the Torquay Protocol to the General Agreement on Tariffs and Trade (T. D. 52739), supplemented by Presidential proclamation (T. D. 52836), for imitation semiprecious stones, faceted, and (2) the items marked with the letter “B” at 30 percent under the provision in said paragraph, as modified by T. D. 51802, supplemented by T. D. 51898, for imitation semiprecious stones, not faceted.
[if !vml]>[endif]>

[if !vml]>[endif]>

You have reached the FederalDepository Library Program Electronic Collection (FDLP/EC) Archive. Thisarchive assures ongoing access to publications in the FDLP/EC. Access topublications in the archive is available through GPO's suite of cataloging andlocator services, including the Catalog of U.S. Government Publications(CGP).  Archived copies of publications are retrieved in the event thatpublications are no longer available from the original publishing agency site. 
**Title: ROD--ARMP,Bradshaw-Harquahala**
 
ROD-ARMP
 
Maps:0102030405070809101112131415a15b15c15d15e1617181920212223242526
 
SuDoc Number:I 53.59/2: B 72
Item Number:0629-E-10 (online)
CGP systemNumber: 000681559
 
July 26, 2018
Scudder



Scudder Variable Life Investment Fund
     Money Market Portfolio
     Bond Portfolio
     Balanced Portfolio
     Growth and Income Portfolio
     Capital Growth Portfolio
     Global Discovery Portfolio
     International Portfolio


Supplement to Prospectus
Dated May 1, 1997

Scudder,  Stevens & Clark, Inc. ("Scudder"),  the investment adviser for Scudder
Variable Life Investment  Fund (the "Fund"),  has entered into an agreement with
The Zurich Group ("Zurich"),  an international  insurance and financial services
organization,  pursuant  to which  Scudder  will  form a new  global  investment
organization by combining with Zurich's  subsidiary,  Zurich Kemper Investments,
Inc.,  and  change  its name to  Scudder  Kemper  Investments,  Inc.  After  the
transaction  is  completed,  Zurich  will  own  approximately  70%  of  the  new
organization  with the  balance  owned by the new  organization's  officers  and
employees.

Consummation  of the  transaction  is  subject  to a  number  of  contingencies,
including  regulatory  approvals.  Because the transaction  would  constitute an
assignment of each Portfolio's  investment advisory agreement with Scudder under
the  Investment  Company Act of 1940,  and,  therefore,  a  termination  of each
agreement,  it is anticipated  that Scudder will seek approval of new agreements
from the Fund's  shareholders  prior to  consummation  of the  transaction.  The
transaction is expected to close in the fourth quarter of 1997.



July 18, 1997
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

      ( print page 67322)    
Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Cooperative Centers on Human Immunology (U19 Clinical Trial Optional).                    

*Date:*                         October 31-November 2, 2023.                    

*Time:*                         10:00 a.m. to 6:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G58, Rockville, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Anuja Mathew, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G58, Rockville, MD 20852, 301-761-6911,                         *anuja.mathew@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: September 25, 2023.

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-21356 Filed 9-28-23; 8:45 am]

BILLING CODE 4140-01-P
No. 62802.

#### Inter-Maritime Forwarding Co., Inc. *v.*United States,

protest 58/6613(A) (New York).

Opinion by

Ford, J.

The protest was dismissed.
**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-197408) pertaining to the 2008 Stock Incentive Plan, asamended, the 2014 Equity Incentive Award Plan and the 2014 Employee Stock Purchase Plan of Ardelyx, Inc., of our report dated March 5, 2015, with respect to the financial statements of Ardelyx, Inc. included in this Annual Report (Form 10-K)for the year ended December 31, 2014. 

/s/ Ernst & Young LLP 

Redwood City, California 

March 5, 2015
COURT OF APPEALS OF VIRGINIA 

Present: Judges Humphreys, O’Brien and Senior Judge Bumgardner 

TIER 1, L.L.C. AND 

 TECHNOLOGY INSURANCE COMPANY 

 MEMORANDUM OPINION*

 

v. Record No. 1568-15-2 PER CURIAM 

 FEBRUARY 2, 2016 

DAVID ALBERTO SANDRES-SANCHEZ 

 FROM THE VIRGINIA WORKERS’ COMPENSATION COMMISSION 

 (S. Vernon Priddy III; Stephen A. Marshall; Two Rivers Law Group, 

P.C., on brief), for appellants. 

(Bryan G. Bosta; Becker, Kellogg & Berry, P.C., on brief), for 

appellee. 

 Tier 1, L.L.C. and Technology Insurance Company (appellants) appeal a decision of the 

Workers’ Compensation Commission. Appellants allege the Commission erred in finding the 

evidence sufficient to prove that David Alberto Sandres-Sanchez was an employee of Tier 1, 

rather than an independent contractor, when he sustained an injury by accident arising out of his 

employment. We have reviewed the record and the Commission’s opinion and find that this 

appeal is without merit. Accordingly, we affirm for the reasons stated by the Commission in its 

opinion. See Sandres-Sanchez v. Tier 1, L.L.C., VWC File VA02000017292 (Sept. 1, 2015). 

We dispense with oral argument and summarily affirm because the facts and legal contentions 

are adequately presented in the materials before the Court and argument would not aid the 

decisional process. See Code § 17.1-403; Rule 5A:27. 

 Affirmed. 

 *

 Pursuant to Code § 17.1-413, this opinion is not designated for publication. 

UNPUBLISHED
No. 69262.

#### Azrak-Hamway, Inc., et al. *v.*United States,

protests 62/17115, etc. (New York).

Opinion by

Rao, J.

In accordance with stipulation of counsel that the merchandise consists of battery-operated mixers similar in all material respects to those the subject of Abstract 68674, the claim of the plaintiffs was sustained.
No. 60221.

protest 240348-K (New York).

#### Flower Center, Inc. *v.*United States,

Opinion by

Wilson, J.

In accordance with stipulation of counsel that the merchandise consists of artificial flowers in chief value of feathers, the claim of the plaintiff was sustained.
No. 67125.

protest 62/4575 (New York).

#### Illfelder Importing Co., Inc. *v.*United States,

Opinion by

Oliver, C.J.

In accordance with stipulation of counsel that the merchandise consists of glass paperweights similar in all material respects to those the subject of Abstract 64185, the claim of the plaintiff was sustained.
Maine State Archives 

“Penobscot Tribe - An Act to regulate and Passamaquoddy Tribe 1821,” 

Legislative laws, PL 9-123, Box 9, Chapter 23 

[Transcribed by Micah Pawling]
Maine State Archives 

“Penobscot Tribe - An Act to regulate and Passamaquoddy Tribe 1821,” 

Legislative laws, PL 9-123, Box 9, Chapter 23 

[Transcribed by Micah Pawling]